zaf-uct-trac-2017-2018-v1 DataFirst 2022-08-02 Nesstar Publisher Version 1 Timing of Referral to Antiretroviral Clubs Study 2017-2018 TRAC 2017-2018 zaf-uct-trac-2017-2018-v1 Professor Landon Myer Nesstar Publisher Medical Research Council DataFirst Support Clinical Trial v1: Edited, anonymised data for public distribution Data were collected as part of a randomised controlled trial in which adults stable on ART at four months on treatment were randomised to either ongoing clinic care or referral to the local model of differentiated service delivery (community-based adherence clubs). Data collection included face to face interviews, data abstraction of routine care records and phlebotomy for viral load. South Africa The data is at the level of health facility Individuals Survey and Case Studies Other Questionnaires, data abstraction, phlebotomy. Data collection included face-to-face interviews, data abstraction of routine care records, and phlebotomy for viral load. DataFirst Myer, Landon. Timing of Referral to Antiretroviral Clubs Study 2017-2018 [dataset]. Version 1. Cape Town: University of Cape Town. School of Public Health and Family Medicine [producer], 2018. Cape Town: DataFirst [distributor], 2022. DOI: https://doi.org/10.25828/V71J-3B55 Public access data for use under a Creative Commons CC-BY (Attribution-only) License trac-2017-2018.NSDstat 650 17 Nesstar 200801 Patient identifier 648 2 9001 9220 9109.35 63.238 Study visit number: 1,2, or 3 648 2 1 220 2 216 3 212 Sysmiss 2 Study viral load result (copies/mL) 649 0 100 2 1014 1 106 1 107 1 108845 1 109 3 115 1 116221 1 119 1 120 1 1237 1 1268 1 127 1 12838 1 139 1 1468 1 151 1 154 1 155 1 163 1 167 1 16896 1 169 1 17394 1 174 1 178 1 180 1 187 1 18813 1 191 1 199 1 20 4 2096 1 21 2 22 5 23 5 237 1 2386 1 24 1 25 5 2545 1 26 2 261 1 268 1 27 1 28 5 29 4 30 1 307 1 307654 1 31 1 32 1 33 3 331 1 34 2 341028 1 3433 1 35 1 36 2 37 1 38 2 38161 1 39 1 391 1 40 3 406012 1 41 3 42 1 43 2 432 1 45 1 47 3 476 1 4799 1 48 3 49053 1 50 1 50333 1 51 2 5263 1 53 1 54 2 56 2 561 1 5635 1 5665 1 577 1 59 1 60 1 61 2 624 1 64 2 6459 1 68 1 69 1 70 1 719 1 73 1 77 1 7766 1 78 1 80 2 81 1 86 1 86831 1 94 1 97 1 98 1 <100 7 <20 167 LDL 319 copies/mL 1 WHO stage prior to the initiation of antiretroviral therapy 639 11 1 1 389 2 2 133 3 3 86 4 4 19 5 unknown 12 Sysmiss 11 CD4 count taken pre-initiation of antiretroviral therapy 642 8 1 No 9 2 Yes 633 Sysmiss 8 Value of CD4 count taken pre-initiation of ART (cells/mm3) 633 17 5 1347 395.316 234.488 Model of care to which participant was randomised at enrolment 648 2 1 Clinic 318 2 Club 330 Sysmiss 2 Currently working/studying 648 2 1 No 228 2 Yes 420 Sysmiss 2 Major source of income for household 648 2 1 Disability grant 15 2 Full-time employment 384 3 Informal employment 74 4 None 9 5 Other 23 6 Other grant 6 7 Part-time employment 84 8 Pension 12 9 Social grant 41 Sysmiss 2 Current antiretroviral therapy regimen 648 2 1 Tenofovir + Emtricitabine + Efavirenz 648 Sysmiss 2 Prior lifelong antiretroviral therapy 648 2 1 No 495 2 Yes 153 Sysmiss 2 Duration on antiretroviral therapy at enrolment (days) 648 2 -98 154 128.377 19.914 Duration on antiretroviral therapy at 2nd study visit (days) 644 6 202 369 255.615 25.834 Duration on antiretroviral therapy at 3rd study visit (days) 636 14 315 452 368.623 22.257 Attended second study visit within visit window 650 0 0 27 1 623 Attended third study visit within visit window 650 0 0 35 1 615 Included in the per protocol analysis 648 2 0 60 1 588 Sysmiss 2